Cytochrome P450 2A6 (CYP2A6) is the primary human enzyme involved in nicotine metabolism. The objective of this study was to characterize two nonsynonymous single nucleotide polymorphisms in CYP2A6*24, 594G4C (Val110Leu) and 6458A4T (Asn438Tyr). We determined their haplotype, allele frequencies, effect on CYP2A6 activity in vivo, as well as their stability and ability to metabolize nicotine in vitro. CYP2A6*35 (6458A4T) occurred at a frequency of 2.5-2.9% among individuals of black African descent, 0.5-0.8% among Asians and was not found in Caucasians. In addition, we identified two novel alleles, CYP2A6*36 (6458A4T and 6558T4C (Ile471Thr)) and CYP2A6*37 (6458A4T, 6558T4C and 6600G4T (Arg485Leu)). In vivo, CYP2A6*35 was associated with lower CYP2A6 activity as measured by the 3HC/COT ratio. In vitro, CYP2A6.35 had decreased nicotine C-oxidation activity and thermal stability. In conclusion, we identified three novel CYP2A6 alleles (CYP2A6*35, *36 and *37); the higher allele frequency variant CYP2A6*35 was associated with lower CYP2A6 activity.
Introduction
Cigarette's addictive properties are largely due to the psychoactive effects of nicotine. 1 Owing to the relatively short half-life of nicotine, approximately 2 h, 2 dependent smokers smoke at regular intervals to maintain nicotine levels. Therefore, factors that influence the intake or removal (for example, metabolism) of nicotine from the body can affect smoking behaviors such as the number of cigarettes smoked or the likelihood of cessation. [3] [4] [5] [6] In vivo, 70-80% of nicotine is metabolized to cotinine (COT), 2 and cytochrome P450 2A6 (CYP2A6) mediates approximately 90% of this reaction. 7, 8 CYP2A6 also exclusively mediates cotinine's hydroxylation to trans-3 0 -hydroxycotinine (3HC), making the metabolic ratio of 3HC/COT a specific and reliable marker of CYP2A6 activity. [9] [10] [11] The 3HC/COT ratio correlates with the rate of nicotine clearance 10 and is stable over time, 12 thereby facilitating its use as a proxy measure for the rate of CYP2A6-mediated nicotine metabolism in population studies. A common feature of nicotine pharmacokinetic studies is the large interindividual variability in the rate of metabolism. [13] [14] [15] Sources of this large variability may include environmental (for example, smoking), physiological (for example, systemic diseases) and genetic (for example, CYP2A6 polymorphisms) factors. 16 Recently, we characterized the effect of a number of established and novel CYP2A6 alleles on CYP2A6 activity and nicotine disposition kinetics in a population of black African descent. 15 Interestingly, most of the novel alleles were associated with lower in vivo CYP2A6 activity, accounting for some of the previously uncharacterized variability and slower nicotine metabolism in this population. Nonetheless, even after controlling for gender, smoking and known CYP2A6 alleles, large variability in CYP2A6 activity still remains. One possible source of the remaining variation is the presence of additional genetic variants. Through sequencing, we found that CYP2A6*24 contains two nonsynonymous single nucleotide polymorphisms (SNPs): 594G4C (Val110Leu) and 6458A4T (Asn438Tyr). 15 A question that remained is whether 594G4C or 6458A4T can occur on their own, and if so, what are their allele frequencies and functional impact on CYP2A6 activity.
In the current study we genotyped multiple ethnic populations for 594G4C (Val110Leu) and 6458A4T (Asn438Tyr), assessed their allele frequencies and examined their impact on in vivo CYP2A6 activity using the 3HC/COT ratio. In addition, we created cDNA-expressed variants CYP2A6.V110L (Val110Leu), CYP2A6.35 (Asn438Tyr), CYP2A6.24 (Val110Leu þ Asn438Tyr) and assessed their thermal stability and ability to metabolize nicotine to cotinine in vitro using an Escherichia coli heterologous expression system.
Results
Allele frequency of CYP2A6*35 and identification of novel alleles CYP2A6*36 and CYP2A6*37 Because CYP2A6*24 is a haplotype containing 594G4C and 6458A4T, 15 individuals positively genotyped for these two variants were considered to have CYP2A6*24, whereas individuals positively genotyped for 6458A4T alone formed the CYP2A6*35 group. We did not find any individuals with the 594G4C SNP alone in any of the ethnic groups. CYP2A6*24 occurred at an allele frequency of 0.7% among African-American smokers (n ¼ 1234 alleles) and was not found among Caucasians (n ¼ 304 alleles), Japanese (n ¼ 120 alleles), Chinese (n ¼ 196 alleles) or Taiwanese (n ¼ 334 alleles). Alleles here are inferred by assuming that each individual has two copies of chromosome 19 containing one allele on each chromosome. Previously we found CYP2A6*24 at a frequency of 1.3% among an African Canadian population (1.4% in smokers and 1.1% in nonsmokers) and characterized it as a low-activity variant.
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CYP2A6*35 was found among individuals of African descent with a frequency of 2.9 and 2.5% in African-American smokers and African Canadians (1.8% in smokers and 3.3% in nonsmokers), respectively. The allele was also found in Japanese (0.8%), Taiwanese (0.6%) and Chinese (0.5%) but not among Caucasians. The genotype frequencies of CYP2A6*24 and CYP2A6*35 did not significantly deviate from Hardy-Weinberg equilibrium in any population.
The variant CYP2A6*35 alleles from one African Canadian, one African American and one Taiwanese individual were fully sequenced. The variant allele CYP2A6*35A was identical among the African-American and African Canadian individuals, whereas the allele CYP2A6*35B in the Taiwanese individual differed modestly ( Table 1 ). The allele frequencies of CYP2A6*35 presented herein include both CYP2A6*35A and CYP2A6*35B. In addition, we identified two novel alleles, CYP2A6*36 and CYP2A6*37. CYP2A6*36 contains 6458A4T in haplotype with 6558T4C present in CYP2A6*7, whereas CYP2A6*37 contains 6458A4T and two additional SNPs present in CYP2A6*10 (6558T4C and 6600G4T; Table 1 ). CYP2A6*36 and CYP2A6*37 were only found among Taiwanese individuals, both at a frequency of 0.3%. These alleles were not included in estimating the allele frequency of CYP2A6*35.
CYP2A6*35 is associated with lower CYP2A6 activity in vivo
In the African Canadian population, individuals with CYP2A6*1/*35 genotype had significantly lower mean 3HC/COT compared to those in the wild-type group (CYP2A6*1/*1; Table 2 ). Four individuals were compound heterozygotes, one having CYP2A6*9/*35 and three having CYP2A6*17/*35. All four individuals had substantially lower 3HC/COT ratios compared to wild-type and heterozygote CYP2A6*1/*35 individuals (Table 2) .
Among the African Americans, those with CYP2A6*1/*35 genotype also had significantly lower mean 3HC/COT compared to individuals in the wild-type group (CYP2A6*1/*1; Table 2 ). In addition, an individual homozygous for CYP2A6*35 had lower 3HC/COT compared to the heterozygous individuals suggestive of a gene-dose effect. As seen in the African Canadian population, this population had compound heterozygote individuals (CYP2A6*9/*35, n ¼ 2; CYP2A6*17/*35, n ¼ 3) with lower 3HC/COT values compared to wild type.
In vitro enzymatic activities of the CYP2A6 variants The apparent K m and V max values for nicotine C-oxidation by CYP2A6.1 and the variant constructs are presented in To determine whether the amino-acid changes could affect protein stability we tested the thermal stability of the constructs by incubating them at 37 1C and collecting aliquots at various times to measure nicotine C-oxidation CYP2A6*35 reduces enzyme activity N Al Koudsi et al activity and CYP2A6 protein levels. Generally, the activity of the variant constructs decreased to a greater extent compared to the wild-type construct (Figure 1a) . The time it took to decrease CYP2A6 activity by 50% (t 1/2 ) was significantly shorter for CYP2A6. 17 The number of individuals with greater than one variant was too small for statistical analyses. The P-value obtained does not include the homozygote CYP2A6*35 individual. The ratio was derived from plasma metabolite levels following oral nicotine intake or ad libitum smoking among the African Canadian and African American population, respectively. The effect of CYP2A6*35 remained significant in both populations when the wild-type group was restricted to individuals with at least one CYP2A6*1B allele (i.e., CYP2A6*1A/*1B and CYP2A6*1B/*1B). The 3H/COT ratios among individuals with CYP2A6*35 compared to individuals with only CYP2A6*1B were as follows: 0.84 ± 0.50 vs 1.25 ± 0.66, P ¼ 0.03 among African Canadians and 0.75 ± 0.26 vs 1.38 ± 0.75, Po0.001 among African Americans. The P-values are from the regression model as described in the Materials and methods section with the dependent variable being log 3HC/COT, controlling for gender and smoking. When the data were analyzed with a Mann-Whitney test where the dependent variable was 3HC/COT (i.e., not lognormalized), and where the effects of gender and smoking were not considered, the effect of CYP2A6*35 remained significant in both populations (African Canadian P ¼ 0.016 and the African American P ¼ 0.001). 6458A4T (N438Y, exon 9) 6458A4T (N438Y, exon 9) 6458A4T (N438Y, exon 9) 6558T4C (I471T, exon 9) 6558T4C (I471T, exon 9) 6600G4T (R485L, exon 9)
Numbering of the nucleotides is in reference to the ATG start site of the CYP2A6 gene (reference genomic sequence NG_000008.7) in which A is numbered 1 and the base before A is numbered À1. Bolded nucleotides are synonymous SNPs. Bolded and italicized nucleotides are nonsynonymous SNPs. 2A6*1B refers to the 58 bp gene conversion in the 3 0 untranslated region that was present in all alleles. 
Discussion
The focus of the present study was two SNPs found in CYP2A6, 594G4C and 6458A4T. Here, we did not find individuals with 594G4C alone, suggesting that 594G4C is in obligate haplotype with 6458A4T forming CYP2A6*24.
Conversely, individuals with only 6458A4T were found. The allele containing 6458A4T was sequenced and assigned the name CYP2A6*35 by the CYP allele nomenclature committee (http://www.cypalleles.ki.se/). CYP2A6*35 was predominantly found among individuals of African descent and to a lesser extent among individuals of Asian descent. The CYP2A6*35 allele sequence differed slightly between African and Asian descent distinguishing it as CYP2A6*35A and CYP2A6*35B, respectively. We also discovered two novel alleles among Taiwanese individuals where the 6458A4T SNP was in haplotype with 6558T4C in CYP2A6*7 or 6558T4C þ 6600G4T in CYP2A6*10, forming CYP2A6*36 and CYP2A6*37, respectively. We could not test the functional in vivo consequence of CYP2A6*36 and CYP2A6*37, but because both of these rare alleles contain the amino-acid substitution (Ile471Thr) found in CYP2A6*7 and CYP2A6*10, it is likely they will result in a loss of function. The substitution Ile471Thr has been associated with lower CYP2A6 activity and stability in vitro (E. coli system) 17 in addition to lower in vivo CYP2A6 activity in multiple studies. [18] [19] [20] [21] Our in vivo data strongly suggest that CYP2A6*35 is associated with lower CYP2A6 activity. In both African populations, individuals heterozygous for CYP2A6*35 had B70% of the activity of the wild-type CYP2A6 group, a reduction in activity that is similar to well-characterized decreased function alleles CYP2A6*9, CYP2A6*12 and CYP2A6*17.
14,15,22 Several case-control studies have associated CYP2A6 genetic variants that result in lower CYP2A6 activity with a lower likelihood of smoking; 5, 23 however, negative findings have also been reported. 24, 25 Among the African Canadians, a trend was observed in which individuals with CYP2A6*35 were less likely to be current adult smokers (OR ¼ 0.51; 95% CI ¼ 0.17-1.60, P ¼ 0.19). The allele frequency of CYP2A6*35 was 3.3% (n ¼ 9, 269 alleles) in smokers compared to 1.8% (n ¼ 5, 275 alleles) in nonsmokers. The magnitude of the effect was the same when analysis was restricted to individuals with only CYP2A6*1/*1 and CYP2A6*1/*35 (OR ¼ 0.39, 95% CI 0.01-1.60, P ¼ 0.19). All the African-American individuals were participants in a smoking cessation trial (that is, smokers) limiting our ability to further test this hypothesis.
Our in vitro enzymatic function data (Table 3) suggest that the variants CYP2A6.V110L (Val110Leu) and CYP2A6.35 (Asn438Tyr) result in lower nicotine C-oxidation activity compared to the wild type. This was driven by the higher apparent K m values observed for CYP2A6.V110L and CYP2A6. 35 . In addition, CYP2A6.V110L and CYP2A6.35 had reduced thermal stability compared to the wild type. The most dramatic reduction in stability was seen following 4 h of incubation, in which the constructs CYP2A6.17, CYP2A6.V110L and CYP2A6.35 lost more than 50% of their initial activity, whereas the wild-type (CYP2A6.1) lost only about 30% of its initial activity. It is interesting to note that the amino-acid substitutions Val110Leu and Asn438Tyr are not highly conserved among the CYP2A family. For instance, the human CYP2A13 and the mouse CYP2A5, both of which metabolize nicotine efficiently, have leucine (Leu) at position 110 and tyrosine (Tyr) at position 438. In addition, the physical and chemical properties of valine (Val) and leucine (Leu) and asparginine (Asn) and tyrosine (Tyr) are similar to each other (for example, Val and Leu are similarly aliphatic, whereas Asp and Tyr are similarly polar). It is possible though that the positions of the following amino-acid changes are important. Valine 110 resides within the substrate recognition site 1 (residues 101-120) 26 and is in very close proximity to the active site of CYP2A6. 27, 28 Thus, this substitution (Val110Leu) might alter the active site cavity. 28 On the other hand, asparginine 438 resides on the surface of CYP2A6 and is situated next to the conserved heme-binding cysteine 439. 26, 29 Thus, it is possible that the amino-acid substitution Asn438Tyr might affect the binding of the heme. In our study the reduction in protein levels did not fully complement the reduction in CYP activity suggesting that the heat treatment might have also facilitated the loss of heme. We were unable to test this (due to the low sensitivity of our assay); however it would be valuable in the future to determine the stability of the holoenzyme by obtaining the CO difference spectrum for the constructs.
It was surprising for us to find that individually Val110Leu and Asn438Tyr reduced CYP2A6 activity and stability, whereas in CYP2A6.24 the occurrence of both amino-acid changes appeared to have stabilized the enzyme. This is in contrast to our previously published study, 15 in which individuals with CYP2A6*24 were associated with lower CYP2A6 activity measured by the 3HC/COT ratio in vivo. There are several possible reasons for the discordance between the in vivo and in vitro data for CYP2A6*24. It is possible that the coding SNPs might be affecting protein degradation (discussed below). Alternatively, the coding SNPs might be in linkage disequilibrium with polymorphisms in the gene promoter or within introns that affect transcription and mRNA splicing, and as a result might influence function in vivo. For example, CYP2A6*35A and CYP2A6*24 contain À1013A4G, which is thought to disrupt a putative enhancer region, 30 whereas CYP2A6*35B
contains À745A4G that is thought to disrupt a CCAAT box to which the regulatory element NF-Y binds. 31 Both of these promoter SNPs have been shown to result in decreased expression in a reporter construct system. 30, 31 The protein levels of CYP2A6.1 did not appear to decrease during the first 12 h of incubation, although its activity did. This is likely due to the fact that immunoblotting not only detected functional holoenzyme, but also apoenzyme and misfolded CYP2A6. However, it is interesting to note that unlike CYP2A6.1, the CYP2A6 protein levels of the variant constructs all decreased with incubation time suggesting that these constructs are more susceptible to degradation. It was also noted that the CYP2A6 variant constructs had lower CYP2A6 protein expression (pmol of CYP2A6 per mg of membrane protein) compared to the wild-type construct following culturing of the E. coli. There is a growing body of evidence for nonsynonymous coding SNPs influencing enzymatic function by decreasing the amount of protein through accelerated degradation. [32] [33] [34] [35] Much of this evidence comes from cytoplasmic proteins such as thiopurine Smethyltransferase, 32 and has also been shown for cytochrome P450. For example, Bandiera et al. 35 demonstrated that CYP1B1.4 is expressed at lower levels compared to CYP1B1.1 in COS-1 cells largely due to its increased rate of degradation.
The present study suggests that CYP2A6*35 is associated with lower in vivo CYP2A6 activity, likely due to its lower nicotine C-oxidation activity, stability and greater susceptibility to protein degradation. Because of its lower stability, CYP2A6*35 is likely to result in lower in vivo activities toward all CYP2A6 substrates; however this remains to be tested. In conclusion, we have identified several novel alleles (CYP2A6*35, CYP2A6*36 and CYP2A6*37), one of which (CYP2A6*35) is found at a relatively high frequency among individuals of African descent and is associated with lower CYP2A6 activity in vivo. Identifying and characterizing novel CYP2A6 variants among different ethnic groups will help refine the relationship between CYP2A6 genotype and nicotine metabolism phenotype, thus increasing the utility of genotyping in epidemiological and clinical treatment studies. 15, 36, 37 Materials and methods CYP2A6 6458A4T genotype assay A two-step PCR assay was developed to detect the 6458A4T SNP based on the reference genomic sequence NG_000008.7. The first PCR reaction amplified a genespecific region from intron 6 to the 3 0 -flanking region using the primers 2A6in6F1 and 2A6R0 as described previously. 38 In the second PCR reaction, an allele-specific region (1327 bp) from exon 9 to the 3 0 -flanking region of CYP2A6 was amplified using one of the two forward primers 2A6in8ex9F6458W or 2A6in8ex9F6458V in combination with one reverse primer 2A6R0 (Table 4 1C for 1 min, followed by a final extension at 72 1C for 5 min. 594G4C was detected as described previously. 15 The PCR products were analyzed by electrophoresis on a 1.2% agarose gel (OnBio, Richmond Hill, Canada) stained with ethidium bromide. The assay was developed using multiple cosmids containing genomic clones of CYP2A6 as a positive control and CYP2A7 and CYP2A13 as negative controls (provided by Dr Linda Ashworth, Human Genome Centre, Liverpool).
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CYP2A6 sequencing To confirm our genotyping assay and determine the haplotype of the allele, we amplified (long PCR) and sequenced a 9.2 kb fragment containing the CYP2A6 gene from three individuals heterozygous for 6458A4T (one African Canadian, one African American and one Taiwanese). The 25 ml PCR reaction used the primers 2A65Pr1F and 2A6R0 (Table 4 ) and was performed following the manufacturer's instructions (long PCR enzyme mix; MBI Fermentas) with the following minor modifications. The annealing temperature was 57 1C and the reaction contained 75 ng of DNA, 0.3 mM of each dNTP and 0.25 mM of each primer. The PCR product was subcloned and sequenced as described previously. 15 In addition, the CYP2A6 gene (9.2 kb) of two individuals was amplified. One was genotyped as having 6458A4T as well as 6558T4C present in CYP2A6*7, whereas the other was genotyped as having 6458A4T and 6558T4C þ 6600G4T present in CYP2A6*10. Following CYP2A6 gene (9.2 kb) amplification the products were cloned and then genotyped or sequenced to determine whether 6458A4T is in haplotype with the SNPs in CYP2A6*7 and CYP2A6*10.
CYP2A6 genotyping and phenotyping
Individuals from different ethnic backgrounds, African Canadian (n ¼ 279), African American (n ¼ 617), Japanese (n ¼ 60), Taiwanese (n ¼ 167), Chinese (n ¼ 98) and Caucasian (n ¼ 152) were genotyped for the 6458A4T variant. In addition, the African Americans and African Canadians were genotyped for other CYP2A6 variants including CYP2A6*1B, *2, *4, *9, *12, *14, *17, *20, *21, *23, *24, *25, *26, *27 and *28), whereas the Taiwanese, Chinese, Japanese and Caucasians were genotyped for CYP2A6*1B, *2, *4, *7, *8, *9, *10 and *12. The demographics of the African Canadian, African-American, Japanese, Chinese, Taiwanese and Caucasian populations have been previously described. 5, 40, 41 Phenotypic measures were available for the African Canadian and African-American populations. The plasma 3HC/COT ratio collected at 270 min following oral nicotine (4 mg capsule) was used as a proxy measure for CYP2A6 activity among the African Canadians, 41 whereas the plasma 3HC/COT ratio collected from ad libitum smoking 10 was used in the African-American population. 22 In both populations CYP2A6 genotype has been shown to be significantly associated with the ratio (3HC/COT), supporting its use as a measure of CYP2A6 activity. 15, 42 All studies were approved by ethics board of the University of Toronto.
Construction and expression of CYP2A6 constructs in E. coli A bicistronic construct containing the full-length cDNA of CYP2A6 followed by the human nicotinamide adenine dinucleotide phosphate oxidase (NADPH)-cytochrome P450 reductase (hNPR) inserted into a pCW expression vector was generously provided by Dr E Gillam. 43, 44 Two amino-acid substitutions, V110L and N438Y, were introduced either alone or in combination to create CY-P2A6.V110L, CYP2A6.35 (Asn438Tyr) and CYP2A6.24 (Val110Leu þ Asn438Tyr), respectively. The commercial kits QuickChange II XL Site-Directed Mutagenesis and QuickChange Multi Site-Directed Mutagenesis were used to introduce the single and multiple amino-acid substitutions, respectively, according to the manufacturer's directions (Stratagene, La Jolla, CA, USA). Primers used to introduce Val110Leu (CYP2A6.V110L) were 2A6_594G4C and 2A6_594G4C Anti (Table 4) . Asn438Tyr (CYP2A6.35) was introduced using the primers 2A6_6458A4T and 2A6_6458A4T Anti (Table 4 ). The combination of 2A6_594G4C Anti and 2A6_6458A4T Anti was used to Mwenifumbo et al. 38 .
CYP2A6*35 reduces enzyme activity N Al Koudsi et al construct CYP2A6.24 (Val110Leu þ Asn438Tyr). Introduction of the correct changes to the variant constructs was confirmed by sequencing. In addition, a construct with 802 bp deleted from the CYP2A6 cDNA (CYP2A6.NEG) was used as a negative control, whereas a CYP2A6.17 construct served as a positive control. 44 All five variant constructs (CYP2A6.NEG, CYP2A6.17, CYP2A6.V110L, CYP2A6.35 and CYP2A6.24) in addition to the wild-type CYP2A6 (CYP2A6.1) were expressed in E. coli and membrane fractions were prepared as described previously. 44 Membrane protein content was determined by the Bradford protein assay (Bio-Rad Labs, Mississauga, Ontario, Canada) and the amount of CYP2A6 protein was determined by immunoblotting with a monoclonal CYP2A6 antibody (BD Biosciences, Mississauga, Ontario, Canada) as described previously. 44 In vitro nicotine assay Nicotine C-oxidation activity was assessed as previously described with minor modifications. 44 The reaction mixture (final volume of 0.5 ml) contained E. coli membrane preparations (10 pmol CYP2A6), 20 nmol l À1 of expressed cytochrome b 5 (Invitrogen, Burlington, Canada), 50 mmol l À1 Tris-HCL buffer (pH 7.4), 1 mmol l À1 NADPH (Sigma-Aldrich, Oakville, Canada), nicotine substrate (ranging from 2 to 100 mM), and 1.0 mg protein per ml human liver cytosol (added in excess so that CYP-mediated oxidation would be rate limiting). The reaction was initiated by the addition of 1 mmol l À1 NADPH following a 2 min preincubation at 37 1C. After 15 min incubation, the reaction was stopped by the addition of 100 mM of Na 2 CO 3 . Cotinine formation was determined by high-pressure liquid chromatography as described previously. 45 Cotinine formation increased linearly with CYP2A6 protein concentrations (5-70 pmol) and time (5-30 min) at 100 and 500 mM of nicotine (data not shown). The minimal amounts of cotinine detected in the reaction with CYP2A6.NEG were used as baseline correction to control for any contamination of the substrate or cotinine formation by the E. coli system. The kinetic parameters (V max and K m ) were estimated from the high-affinity site using the Michaelis-Menten equation in the computer program GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA version 5.0 for Windows).
In vitro thermal stability assay To test the thermal stability of the different CYP2A6 constructs, E. coli membrane preparations were incubated at 37 1C for 24 h. The experiment was carried out twice independently. On one day, single aliquots were collected, whereas on the other day duplicate aliquots were collected. Data were consistent within and between days. Aliquots were taken at 0, 4, 8, 12 and 24 h to measure nicotine Coxidation activity. Activity assays were carried out with 30 mM of nicotine as described above. In addition, aliquots were taken at 0, 8, 12 and 24 h to measure CYP2A6 protein levels by immunoblotting.
Statistical analyses
Hardy-Weinberg equilibrium was tested using w 2 -or Fisher's exact test if five or fewer individuals were in one genotype group. Because gender and smoking status significantly influence the 3HC/COT ratio in the African Canadian population 46 and other populations, [47] [48] [49] we controlled for gender and smoking. The African-American population were all smokers, thus we only controlled for gender. Throughout the paper the 3HC/COT ratio is presented as the mean adjusted value. The adjustment for the impact of gender and smoking status was made as previously described. 15 Briefly, the metabolic ratio for each individual was adjusted by dividing the 3HC/COT value with the overall mean from their respective group. For example, the 3HC/COT of each female nonsmoker was divided by the overall mean of their respective group (that is, female nonsmokers). The mean adjusted ratios were not used in any statistical analyses. Instead we used the raw 3HC/COT values and controlled for the effects of gender and smoking using a regression model. We adopted a forward step-wise regression strategy in which gender and/or smoking status were in the first block and CYP2A6 genotype in the second block. The reference for CYP2A6 genotype in the regression analyses was that with wild-type genotype (CYP2A6*1/*1) and the dependent variable was log 3HC/COT. The wild-type genotype group (CYP2A6*1/*1) included individuals with undetected CYP2A6 variants and the wild-type variant CYP2A6*1B. The CYP2A6*1B allele was included in the wild-type group (CYP2A6*1/*1) for two main reasons. First, the SNPs in CYP2A6*35 are found on the CYP2A6*1B background, meaning they are in linkage with the 58 bp gene conversion found in CYP2A6*1B (Table 1) . Second, CYP2A6*1B is a wildtype allele usually included in the wild-type reference group in the literature, 15, 18 along with other variants of the CYP2A6*1 allele (CYP2A6*1B-*1K, listed at http://www. cypalleles.ki.se/cyp2a6.htm). To compare the impact CYP2A6*35 to other variants in the literature, we have included the individuals with CYP2A6*1B in the wild-type (CYP2A6*1/*1) group. The 3HC/COT values were lognormalized as the 3HC/COT values were not normally distributed.
In vitro kinetic parameters (V max , K m , V max /K m ) of the variant CYP2A6 constructs were compared to the wild-type CYP2A6 construct using one-way analysis of variance followed by the Bonferroni post hoc test. The half-life (t 1/2 ) for the thermally induced loss of CYP2A6 activity was determined according to the one-phase decay equation (GraphPad Prism, version 5). The t 1/2 values reported herein are a measure of the thermal activity of the enzyme as previously determined 17, 50 and not the t 1/2 of the CYP2A6 protein. Time courses of multiple experiments performed were analyzed in concert to obtain the value of the rate of decay k; which was subsequently used to determine the halflife (t 1/2 ¼ ln2/k). By fixing the value of k obtained for the wild type (CYP2A6.1), the changes in the absolute sum of squares of the variant constructs were compared to their baseline fits to determine the level of significance. All analyses were performed on the collected data, whereas the CYP2A6*35 reduces enzyme activity N Al Koudsi et al data were normalized as the percentage remaining activity for presentation. All P-values are one tailed with Po0.05 considered statistically significant. Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA version 15.0 for Windows) and GraphPad Prism (GraphPad Software Inc., version 5.0 for Windows).
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